INTRODUCTION
The Ras family of small GTPases regulates a host of cellular processes, including proliferation, differentiation and survival. This protein family functions as a molecular switch, transitioning from an inactive GDP-bound to an active GTP-bound state when triggered by signalling from receptor tyrosine kinases via the activation of GEFs (guanine-nucleotide-exchange factors). In the active GTP-bound state, Ras proteins interact with downstream effectors, such as Raf, Ral-GEF and PI3K (phosphoinositide 3-kinase), to transmit signals from the cell membrane to intracellular signalling pathways that ultimately influence gene transcription and therefore regulate cellular function (see [1] for a comprehensive review).
The three isoforms of Ras (HRas, KRas and NRas) share a high degree of homology, with the principal differences occurring at the C-terminus. It is this region that dictates the post-translational modifications that are thought to influence intracellular localization. It has been hypothesized that the distinct functions of the three isoforms of Ras may arise from differential localization and the availability of downstream effectors at these particular locations (reviewed in [1, 2] ). However, much of the research dedicated to identifying the differences in activity, localization and overall function of the three Ras isoforms has been performed using overexpressed Ras that is often fused to affinity tags such as GFP (green fluorescent protein). There is strong evidence suggesting that there are significant differences in the activity, localization and cellular responses to overexpressed Ras compared with Ras expressed at endogenous levels [3, 4] . Other studies have utilized siRNAs (short interfering RNAs)/shRNAs (short hairpin RNAs) targeting Ras, an approach that has inherent off-target effects and often does not lead to the complete deletion of a gene product.
Mutations in the Ras genes are prevalent in human tumours, appearing in approximately one-quarter of all cases. Mutations primarily occur at the Gly 12 , Gly 13 or Gln 61 positions, all of which decrease the rate of GTP hydrolysis, thereby allowing Ras to remain constitutively active. It has been assumed that the constitutively GTP-bound mutant Ras will be dominant over the WT (wild-type) protein and the other isoforms in signalling to its effectors and activating gene expression. However, most of the studies that demonstrate the activation of ERK (extracellularsignal-regulated kinase) and PI3K signalling by mutant Ras have employed an overexpressed version of the mutant gene (for example, [1, 5] ), whereas the analyses of cell signalling following knockin of mutant Ras genes show surprisingly modest consequences on ERK and Akt phosphorylation [2, [6] [7] [8] . In all of these studies, pathway activation remained dependent on growth factor stimulation, suggesting that the high level of GTP-bound mutant allele was not sufficient to activate these downstream pathways and that WT Ras isoforms might thus contribute. There is also evidence that the Ras isoforms differentially activate downstream effector pathways. For example, HRas has been suggested to preferentially activate PI3K signalling, whereas KRas might preferentially activate Raf [3, 4, 9, 10] .
There is accumulating evidence that WT Ras can behave as a tumour suppressor under certain conditions. Loss of the WT Ras allele is observed in chemically induced tumours that involve NRas [11] , HRas [12] and KRas [13] mutations. In addition, the deletion of one WT KRas allele increased the incidence and severity of lung tumours resulting from chemically mutated KRas [14] . The deletion of a single WT NRas allele increased the number of tumours induced by a variety of agents, including mutant NRas, in mouse tumour models [15] . This phenomenon is also apparent in the defined conditional Ras mutation models [16] . Evidence exists to indicate that the overexpression of WT Ras suppresses tumour formation [17, 18] , although this may be partly due to competition for the endogenous Ras processing machinery. In contrast with these reports that indicate a tumour-suppressive role for WT Ras, some data suggest that the WT Ras isoforms may be required for mutant Ras-induced tumours. In two pancreatic xenograft tumour models driven by mutant KRas, the deletion of WT HRas or NRas decreased tumour burden [19] . This may result from increased GTP binding of WT Ras via the activation of Sos (Son of sevenless) by mutant KRas [20] . Clearly, there is still much to be learned regarding the interplay among the WT Ras alleles and isoforms in mutant Ras-driven tumours.
ZFNs (zinc-finger nucleases) are a recently harnessed tool to induce site-specific genomic DNA alterations (reviewed in [21, 22] ). They are modular proteins enabled with two important functions: the ability to bind specific DNA sequences via zincfinger DNA-binding domains and the ability to create a doublestrand break via the action of the Fok1 endonuclease. Upon introduction into a cell, ZFNs bind to the targeted DNA sequence, homodimerize and create a double-strand break. This break is repaired either by imperfect NHEJ (non-homologous end-joining) or by HR (homologous recombination) with an exogenous sequence or the other endogenous allele. The cellular process of NHEJ can result in deletions and insertions at the ZFN cut site that can be exploited when they modify the translated protein sequence. In this way, gene deletions are obtained with minimal (as small as one base pair) alterations to the endogenous genomic landscape. By taking advantage of HR, gene modifications such as fusion tags and mutations can be introduced into the endogenous gene locus. In the present study, we used ZFNs targeting HRas and NRas to uncover the requirement of these proteins in the context of mutant KRas-driven signalling, proliferation and tumorigenesis in the Hec1A endometrial cancer cell line.
EXPERIMENTAL

Cell lines
The Hec1A endometrial cancer cell line and the derivatives lacking WT or mutant KRas were a gift from Dr Todd Waldman (Lombardi Comprehensive Cancer Center, Georgetown University, School of Medicine, Washington, DC, U.S.A.) and were maintained in McCoy's 5A (Life Technologies) supplemented with 10 % (v/v) FBS (fetal bovine serum) (SigmaAldrich) (growth medium). Custom ZFNs targeting HRas and NRas were purchased from Sigma-Aldrich. The genomic regions that were targeted are as follows: HRas, CCTGCCAGCAGCTGCCCTGtggggcCTGGGGCTGGGCCTG and NRas, CAGCTAATCCAGAACcactttGTAGATGAATATGAT (lower-case letters indicate the cut site) (Supplementary Figure S1 at http://www. biochemj.org/bj/452/bj4520313add.htm). The HRas and NRas ZFN pairs were nucleofected into Hec1A cells (4 μg of ZFN mRNA or DNA) using Lonza reagents. To create the HRasknockout lines, 8 μg of targeting vector encompassing a 395 bp deletion of exon 2 was also included in the nucleofection (Supplementary Figure S1) . After recovering for 2-3 days at 32
• C, the cells were transferred to 37
• C for an additional 3-5 days before being single-cell sorted by FACS into 96-well plates.
Single-cell clones were screened by sequencing for the presence of an alteration at the ZFN site. All cell lines were maintained at 37
• C with 5 % CO 2 .
Western blotting and immunoprecipitation-Western blots
To detect the presence of the Ras isoforms, cells were seeded in 10-cm-diameter Petri dishes in growth medium. At confluence, protein lysates were harvested in RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 % Nonidet P40, 0.5 % sodium deoxycholate and 0.1 % SDS) supplemented with Halt TM Protease and Phosphatase Inhibitor cocktail (Thermo Scientific/Pierce). For HRas and KRas, the protein lysate was subjected to immunoprecipitation with an anti-pan-Ras antibody (ab52939, Abcam) followed by pull-down with Protein A-beads (SigmaAldrich) and elution with Laemmli buffer containing 5 % (w/v) 2-mercaptoethanol. The proteins were resolved by SDS/PAGE (12 % gels), transferred on to nitrocellulose, and blotted using antibodies against the following: pan-Ras (ab52939, Abcam), NRas (sc-31, Santa Cruz Biotechnology), HRas (sc-29, Santa Cruz Biotechnology), KRas (sc-30, Santa Cruz Biotechnology) and β-actin (A2228, Sigma-Aldrich).
For signalling experiments, cells were seeded in six-well plates. Near confluence, the cells were starved overnight with medium lacking FBS and then treated with 5 ng/ml EGF (epidermal growth factor) for the time indicated. The protein lysates were harvested and resolved as detailed above. 
Assessment of RasGTP levels
Cells were seeded in 10-cm-diameter Petri dishes in growth medium. At confluence, the cells were starved overnight (medium without FBS) and then treated with 100 ng/ml EGF for 2 min. Protein lysates were prepared and equal amounts (as assessed by the Bradford method; Pierce) were subjected to affinity purification of RasGTP using GST (glutathione transferase)-RBD (Ras-binding domain) according to the manufacturer's instructions (17218, Millipore). The eluted proteins were resolved by SDS/PAGE, transferred on to a nitrocellulose membrane, and blotted using the antibodies in the kit (pan-Ras) or listed above (KRas and NRas).
Colony formation
In 12-well plates, 5000 cells/well were seeded in agar (0.8 %) on top of base agar (1.2 %) containing growth medium. After the agar was set, growth medium was added and replaced twice weekly. Colony formation was assessed at 28 days using the GelCount machine (Oxford Optronics) with a colony size cut-off of 100 μm diameter.
Kinex
TM Antibody Microarrays
Cells were plated in 10-cm-diameter dishes. Upon reaching confluence, the cells were starved overnight and then treated with 10 ng/ml EGF for 6 min. Cell lysates were prepared according to directions provided by Kinexus and then submitted to Kinexus for Kinex TM Antibody Microarrays. The signal quantification was performed with ImaGene 8.0 (BioDiscovery) using predetermined settings for spot segmentation and background correction. The background-corrected raw intensities were log 2 -transformed. To normalize the signal across samples, each sample was shifted to the same median and scaled to the same MAD (median absolute deviation). The follow-up analysis was based on the normalized signal.
cIEF (capillary isoelectric focusing)
Cells were seeded in six-well plates and, upon reaching confluence, were starved overnight and then treated with 5 ng/ml EGF for 5 min. The cells were lysed in 7 M urea, 2 M thiourea, 4 % (w/v) CHAPS, 1 % (w/v) DTT (dithiothreitol), 4 mM spermidine and 1 mM PMSF. The lysate concentrations were determined by the Bradford method using BSA as a standard. cIEF sample mixtures were prepared using 70 % (by volume) Premix G2, pH 5-8 separation gradient (Protein Simple) with 2.5 % (v/v) DMSO inhibitor (Protein Simple), 2.5 % (v/v) Standard Ladder 3 (Protein Simple), 25 % (v/v) cell lysate (0.1 mg/ml) diluted with Bicine/CHAPS buffer (Protein Simple) and urea lysis buffer to achieve a final urea concentration of 1.3 M. The samples were loaded into the capillaries for 25 s and were separated by cIEF over 40 min at 21 000 kDa. The focused protein was then UV cross-linked to the inner capillary surface for 200 s. Immunodetection was performed with a primary anti-total ERK1/2 (040-474, Protein Simple) or anti-phospho-ERK1/2 (040-477, Protein Simple) antibody according to the manufacturer's recommendations. The detection antibodies were loaded into the capillaries, incubated for 120 min, and subsequently incubated with a biotinylated secondary antibody (60 min) and HRP (horseradish peroxidase)-conjugated streptavidin (10 min) (Protein Simple) with a wash between each step. The chemiluminescent signal was induced using luminol/H 2 O 2 (Protein Simple) and was detected at several exposures (15, 30, 60 , 120, 240 and 480 s) to ensure linearity of the response. The data were analysed using the Protein Simple Compass software (version 1.8.2).
Cell proliferation and FACS
Cells were seeded at 5000 cells/well in 96-well plates in growth medium. Cell confluence was monitored using the IncuCyte system (Essen Bioscience). For FACS analysis, the cells were grown to 80 % confluence in six-well dishes in growth medium and then trypsinized and incubated with FITC-labelled annexin V and PI (propidium iodide) for 20 min in the dark. Viable cells (10 000) were analysed, and the associated fluorescence was quantified on a FACSCaliber TM (BD Biosciences).
Tumour xenograft assays
For the xenograft studies, naive BALB/C nude mice (Charles River Laboratories, Hollister, CA) were inoculated subcutaneously with 10 6 Hec1A parental or Ras-modified derivative cells in the presence of 50 % Matrigel TM . The tumours were measured with digital callipers twice per week. The studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Genentech.
RESULTS
Zinc-finger-mediated deletions
ZFN technology was used to target HRas and NRas in the Hec1A endometrial cancer cell line, which contains a single mutant copy of KRas that is required for its transformed phenotype [23] . The ZFNs designed for NRas target the coding region of exon 2, which is the first coding exon, enabling the straightforward isolation of single cell clones with protein-altering genomic modifications. The HRas ZFNs target a region approximately 100 bp upstream of exon 2; deletions long enough to alter the protein-coding region were rare, thereby necessitating a strategy that utilized a targeting vector to obtain deletions of the entire exon (Supplementary Figure S1) .
Using the ZFNs targeted to either HRas or NRas, we created the following derivative clones of the Hec1A parental cell line: (i) two independent lines that completely lack NRas expression, (ii) a single clone that lacks exon 2 of HRas on both alleles, and therefore lacks HRas expression, and (iii) a single clone in which one allele of HRas is completely disrupted and the other allele is modified, but retains partial hypomorphic expression ( Figure 1A) . We evaluated the protein expression of each Ras isoform by Western blotting (Figure 1B) , which demonstrated the complete loss of NRas expression in both derivative clones, the complete loss of HRas in clone H69, and the partial expression of HRas in clone H95. The absolute amount of each isoform was determined by immunoprecipitating total Ras and quantifying each isoform by MS using spike-in isotopically labelled peptides (AQUA) [24] (Supplementary Tables S1 and S2 and Supplementary Figure S2 at http://www.biochemj.org/bj/452/ bj4520313add.htm). The deletion of a particular Ras isoform did not significantly affect the expression of the other Ras isoforms.
We next evaluated the activation status of each Ras isoform under basal, starved and EGF-stimulated conditions by monitoring the GTP-dependent interaction between Ras and its effector Raf. As shown in Figure 1 (C), KRasGTP levels remained relatively constant under different culture conditions and were not affected by the absence of either HRas or NRas. After acute EGF stimulation, NRasGTP levels increased dramatically, and this increase was abolished in the absence of NRas expression ( Figure 1C ). The activation of NRas after EGF treatment was also blunted in the absence of HRas (H69 and, to a lesser extent, H95). We were technically unable to measure HRasGTP levels in these cells using commercially available reagents.
ERK and Akt pathway regulation by HRas and NRas
Given the importance of the Ras pathway in transducing signals from the cell membrane to intracellular signalling cascades, we determined how the loss of either HRas or NRas affected these connections. We utilized an antibody array analysis of 540 panspecific and 270 phospho-specific antibodies, and the full dataset is presented in Supplementary Figure 2A ). To validate the changes in p-ERK from this survey experiment, we performed Western blot analyses, but the changes were too subtle for this method (results not shown). As Western blotting with anti-p-ERK antibodies has been shown to be non-quantitative [25] , we employed cIEF to detect p-ERK. Using this method, we confirmed that cells lacking either NRas or HRas have a diminished EGF-stimulated increase in doubly phosphorylated ERK1 and ERK2 ( Figure 2B , overnight starvation (0 % FBS, S) or starvation followed by 5 min of EGF stimulation (100 ng/ml EGF, E), protein lysates were subjected to immunoprecipitation with the RBD of Raf-1 followed by Western blotting (WB) to distinguish which Ras isoforms were activated. Molecular masses are indicated in kDa.
To validate the decreased phosphorylation of Akt suggested by the antibody arrays, we performed Western blotting using antibodies against p-Akt, as well as against Akt substrates. We confirmed that basal and EGF-stimulated p-Akt was diminished in the HRas-deleted cell lines (Figure 3 ), but, in contrast with the results suggested by the antibody microarray, we did not observe this decrease in the cells lacking NRas. The deletion of HRas resulted in diminished basal and EGF-stimulated phosphorylation of the well-characterized Akt substrates GSK3 and PRAS40 (Figure 3 ).
Cell proliferation and tumorigenic behaviour
The effects on both the ERK and Akt pathways led us to investigate whether the deletion of HRas or NRas influenced the ability of these Hec1A derivatives to proliferate. Using a cell confluency assay, we saw inconsistent effects on the proliferative capacity of the NRas-deleted clones, with one clone (N83) growing slightly faster than the parental Hec1A cells and the other (N179) growing slightly slower. In contrast, the deletion of HRas decreased the proliferation rate of both clonal derivatives ( Figure 4A ). The confluency of the derivative clones at 72 h was significantly different (P < 0.05, Figure 4B ). The HRasdeleted clones also demonstrated a defect in cell spreading after trypsinization and replating, although this resolved itself at later time points (Supplementary Figure S4 at http://www.biochemj. org/bj/452/bj4520313add.htm). We explored potential mechanisms underlying the decrease in cell proliferation/confluency. In cells defective for HRas expression, dual labelling of cells with annexin V and PI revealed increased staining of annexin V, but not PI, indicating increased apoptosis ( Figure 4C ).
The effects of deleting WT KRas, NRas or HRas on tumour formation
To extend these analyses to more relevant tumorigenic assays, we analysed the colony-growth-promoting properties of these clones in soft agar. In this assay, NRas-deleted clones did not display a consistent phenotype, with one clone forming fewer and the other forming more colonies compared with parental Hec1A cells. In contrast, both HRas-modified clones exhibited decreased colony number ( Figure 5A ). Similar results were obtained in another assay of anchorage-independent growth: the assessment of cell proliferation in hanging drops (Supplementary Figure S5 at http://www.biochemj.org/bj/452/bj4520313add.htm). As expected, these analyses confirmed that the deletion of the mutant KRas allele dramatically decreased colony growth. We also determined that the loss of the WT KRas allele increased anchorage-independent growth in both assays, confirming our previous results [26] . To determine whether the deletion of a single copy of NRas or HRas phenocopied the effects of deleting a single WT KRas allele, we analysed three independent clones of the Hec1A cell line that were each lacking a single copy of Lysates from the cell lines indicated were prepared and separated by cIEF in glass capillaries. Following UV cross-linking, antibodies against total ERK1/2 were flowed through the capillary and were detected using HRP-coupled secondary antibodies. The peaks representing doubly phosphorylated (pp-) ERK1 and ERK2 are indicated with arrows. This experiment was performed three times, and a representative experiment is shown. (C) The areas under the peaks in (B) were quantified, and results are means + − differences from the mean for two technical replicates.
Figure 3 AKT signalling is down-regulated in the HRas-deleted cell lines
The cell lines indicated were starved overnight (0 % FBS) and treated with 5 ng/ml EGF for 0, 6, 30 or 120 min. The protein lysates were analysed by Western blotting for the presence of the indicated proteins; β-actin served as a loading control. This experiment was performed nine times, and a representative experiment is shown. Molecular masses are indicated in kDa. Figure S6B) , suggesting that these two isoforms of Ras cannot phenocopy the loss of WT KRas under these circumstances. We next examined the growth of these cells in a murine xenograft model. In concordance with the soft agar assays, the tumour growth of the parental Hec1A cells decreased following the deletion of mutant KRas and increased when WT KRas was deleted ( Figure 5B ). However, decreased proliferation and anchorage-independent growth of the HRas-deleted clones were not observed in the xenograft experiments ( Figure 5B ). NRas-deleted clones exhibited discrepant activity in this assay; compared with the parental line, one clone had diminished tumour growth capacity and the other exhibited slightly increased growth.
HRas or NRas did not increase colony growth (Supplementary
DISCUSSION
In the present study, we used ZFN technology to create derivative clones carrying disrupted copies of HRas or NRas in the Hec1A cell line, which contains a single allele of mutant KRas that has been shown previously to be required for tumorigenicity [23] . Mutant KRas, which is constitutively GTP-bound and fairly unresponsive to further activation (Figure 1 ), does not appear to cause detectable constitutive activation of downstream signalling [1, 23, 26] . In contrast, WT NRas is robustly activated by EGF stimulation and may therefore be a critical Ras isoform in relaying certain growth factor signals to intracellular signalling pathways. Unfortunately, we were unable to assess HRas GTP binding in these cell lines using commercially available reagents, but we expect that its activation would be similar to that of NRas. It therefore appears likely that much of the growth-factorstimulated downstream signalling in mutant KRas cells emanates from WT HRas and NRas. Although the antibody array was useful in surveying a large number of phosphorylated proteins and generating leads for further analysis, our results suggest that only a subset of hits identified from this approach are validated in subsequent experiments. This could be due to many factors, such as differing epitope availability on non-denatured compared with denatured proteins. Nevertheless, we demonstrated that the loss of either HRas or NRas reduced the amount of phosphorylated ERK1 and ERK2 under both starved and EGF-stimulated conditions and that the loss of HRas decreased p-Akt levels as well as those of its substrates (Figures 2 and 3) . It is well established that PI3K can be activated both by interaction of its p85 regulatory subunits with tyrosine-phosphorylated growth factor receptors [27] and by interaction of its catalytic subunit with activated Ras [28] . Interestingly, EGF is a poor direct stimulator of PI3K because EGFR (EGF receptor) does not contain tyrosine residues that lie within the p85-binding motifs [29] , suggesting that most of the EGF-induced PI3K activation could in fact be through Ras. Our data support this model and suggest that HRas in particular is the isoform responsible, a possibility that has been suggested previously by overexpression experiments [9, 10] . It would be interesting to determine whether the modulation of Akt activity through HRas is qualitatively the same as its activation downstream of receptor binding or whether distinct substrates are regulated. A consequence of decreased Akt signalling in the absence of HRas is impaired proliferative capacity, probably stemming from increased apoptosis. The minor alterations in ERK signalling are unlikely to directly affect proliferation or apoptosis because the NRas-deleted cells did not show a consistent decrease in anchorage-dependent or anchorageindependent growth. Together, these data suggest that uniqueness exists among the Ras isoforms in terms of coupling to particular intracellular pathways and that this preferential engagement of downstream effectors leads to diverse cellular responses.
We demonstrated that the loss of the WT KRas allele in Hec1A cells increased the transformed phenotype as was evident from anchorage-independent growth (soft agar and hanging drops) and murine xenograft tumour growth ( Figure 5 ). These data confirm in a human cancer cell line the observations that have been made previously in mouse tumour models [14, 16] . This appears to be a unique property of WT KRas because the loss of a single copy of HRas or NRas did not increase the growth of Hec1A cells in soft agar. The mechanism underlying the tumour-suppressive effect of WT Ras is poorly understood, but the fact that it cannot be mimicked by other isoforms suggests the involvement of a specific cell compartment or effector function that is unique to KRas.
Whereas the contribution of the WT Ras isoforms to biochemical signalling and short-term phenotypic endpoints such as proliferation and apoptosis was evident from our studies, the effects on tumorigenesis were less so. Two different models of anchorage-independent growth suggested that the lack of HRas decreased this aspect of the transformed phenotype, but xenograft tumour growth was not greatly affected. The reason for this discrepancy is not clear; growth in soft agar is often used as a surrogate for xenograft tumour growth. Hec1A cells form slow-growing tumours, suggesting that an additional ratelimiting component other than cell proliferation or survival may dictate tumour growth. Regardless, this has strong implications for the effectiveness of small-molecule compounds that inhibit exchange factor function, such as SCH-54292 [30] , or bind to a similar pocket [31] [32] [33] . Historical data have suggested that mutant KRas activity is independent of Sos function [34, 35] , but more recent experiments indicate that even mutant Ras-driven tumours require WT Ras for downstream signalling [36] and transformation [19, 37] . The facts that Hec1A cells lacking HRas or NRas do not exhibit diminished tumour growth and that WT KRas has tumour-suppressive properties decrease the likelihood of a strong therapeutic index for Sos inhibitors.
The use of ZFNs for genome editing is a powerful new tool for exploring cancer cell biology. However, there is evidence that offtarget genomic alterations can occur. Elegant experiments using integrase-deficient lentivirus vectors to tag transient double-strand breaks demonstrated that ZFNs targeting CCR5 (CC chemokine receptor type 5) and IL2RG (interleukin 2 receptor γ ) bind to and cleave additional genomic sites with homology as low as 67 %, although the frequency of modification at these sites was much lower than that seen at the intended target site [38] . Our analysis of global copy number alterations revealed that the isolated cell clones were not truly isogenic, but instead contained single copy gains and losses throughout the genome. These alterations were more frequent than was expected on the basis of heterogeneity within a pooled cell population because our analysis of two clones isolated from the Hec1A WT cell line contained fewer global genomic alterations than the cell lines treated with ZFNs (Supplementary Figure S7 at http://www.biochemj. org/bj/452/bj4520313add.htm). However, our limited analysis suggests that ZFNs are no more disruptive than conventional HR. Whereas the cell signalling results were consistent between the two clones of each genotype analysed (Figure 2A) , the biological endpoints such as proliferation rate (Figure 4 ) and anchorage-independent growth (Supplementary Figure S6B) produced discrepant data that could be a consequence of the additional genomic alterations caused by off-target nuclease activity. Whether the recently identified TALE (transcription activator-like effector) endonucleases [39] will have less offtarget activity remains to be determined. Nevertheless, both approaches offer a complementary, informative and relatively straightforward alternative to RNAi (RNA interference) technologies, which suffer the consequences of incomplete knockdown and well-documented off-target activities.
In summary, these experiments reveal an under-appreciated requirement for WT Ras alleles in mutant KRas-induced signalling, proliferation and survival, the importance of which in the transformation process remains to be explored further. In addition, our data established that the tumour-suppressive effect of the WT KRas allele cannot be phenocopied by the WT alleles of NRas or HRas. 
EXPERIMENTAL MS analysis of Ras
Protein lysates were prepared in RIPA buffer containing Halt TM Protease and Phosphatase Inhibitor cocktail (Thermo Fisher/Pierce). Then, 1 mg of cleared lysate was incubated with an anti-pan-Ras antibody (ab52939, Abcam) and Protein A beads (Sigma-Aldrich) for 1 h at 4
• C. After stringent washing, the pellets were boiled in SDS sample buffer at 95
• C for 5 min. Eluents were resolved on a 4-20 % Tris/glycine gel (Invitrogen). The 21 kDa band was excised and subjected to in-gel digestion. Gels were destained in 50 mM ammonium bicarbonate in 50 % (v/v) acetonitrile for 15 min and washed with 100 % acetonitrile. A trypsin (Promega) solution at 0.02 μg/μl was added to the gel pieces and chilled on ice for 1 h. Excess liquid was removed. Tryptic digestion was performed at 37
• C in the presence of 25 mM ammonium bicarbonate at pH 8.0 for extraction. On the following day, 500 fmol of synthetic isotopically labelled AQUA peptides was spiked-in. An additional 10 % acetonitrile with 0.1 % trifluoroacetic acid was added to thoroughly extract the peptides. The extracts were combined and dried in a SpeedVac. The peptides were reconstituted in 2 % acetonitrile/0.1 % formic acid and analysed by LTQ-Orbitrap MS (Thermo Fisher).
The absolute amount of WT and mutated Ras was quantified using the AQUA approach [23] . Briefly, peptides specific for wild-type and mutated HRas, KRas, NRas or pan-Ras were synthesized with isotopically labelled amino acids (Table S1) . Then, 100 fmol of each peptide was spiked into the samples after in-gel tryptic digestion but before the MS analysis. LC (liquid chromatography)-MS/MS (tandem MS) was performed on a Waters UPLC instrument coupled to a Thermo LTQOrbitrap mass spectrometer. Full MS at 60 000-resolution and CID (collision-induced dissociation) MS/MS spectra for the eight most abundant peaks were acquired over a 60 min LC run with a 35 min gradient from 2 to 30 % acetonitrile/0.1 % formic acid. The unlabelled endogenous peptides were manually located and quantified using the labelled counterparts as a reference.
InSphero
Cells (4000 cells/40 μl droplet) were seeded in 96-well GravityPLUS hanging-drop plates (InSphero). Every 3 days, 20 μl of growth medium was replaced. After 12 days, the cell clusters were centrifuged into a 96-well plate for imaging and cell number analysis with CellTiter-Glo ® (Promega). The data are an average of eight cell clusters.
Array-comparative genomic hybridization
RNA-free genomic DNA was harvested from each cell line (Qiagen DNeasy kit). Then, 500 ng of DNA from both a test and a reference (male gDNA from Promega) sample was digested with AluI and RsaI (Promega) and subsequently purified using a QIAprep Spin Miniprep kit (Qiagen). Digested samples were labelled with Cy5 (indodicarbocyanine)-dUTP (test sample) or Cy3 (indocarbocyanine)-dUTP (reference sample) using the Genomic DNA Labeling Kit Plus (Agilent Technologies). The test samples were pooled with the reference samples and then purified using MicroCon YM-30 centrifugal filter units (Millipore). The labelled probes were mixed with Cot-1 DNA (Invitrogen), 10× blocking agent and 2× Hi-RPM hybridization buffer (Agilent Technologies) and hybridized to an Agilent 244k human genome CGH (comparative genomic hybridization) microarray. The samples were hybridized for 40 h at 65
• C with a constant rotation of 20 rev./min. Arrays were washed, dried and scanned on an Agilent scanner according to the manufacturer's protocol. Array image files were analysed using Agilent's Feature Extraction software version 9.5. 
Figure S3 cIEF of the ZFN-modified cell lines
Lysates from the cell lines indicated were prepared and separated by cIEF in glass capillaries. After UV cross-linking, antibodies recognizing p-ERK1/2 (top) and Hsp70 (heat-shock protein 70) (bottom) were flowed through the capillary and detected using HRP-coupled secondary antibodies. pp-, dual-phosphorylated. After immunoprecipitation with an anti-pan-Ras antibody, the isoforms of Ras (both WT and mutant) were analysed by MS. Ras isoforms were quantified using AQUA peptides that were unique to the specific isoform, with the exception of mutated KRas and NRas because they lack a unique mutation site. Quantification was performed via AUC (area under the curve) analysis for the chromatographic peaks corresponding to the peptides. 
